Intended for healthcare professionals

CCBYNC Open access

Rapid response to:

Research

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m1091 (Published 26 March 2020) Cite this as: BMJ 2020;368:m1091

Read our latest coverage of the coronavirus outbreak

Rapid Response:

What was the SARS-CoV 2 testing strategy at designated COVID-19 hospital in Wuhan, China?

Dear Editor,

The article by Chen et al. on their experience of managing patients, including those who have have succumbed, with COVID-19 in Wuhan City, China is of interest to those of us tackling the global pandemic[1].

One aspect of the article perplexes me.

The authors are based in the Tongji Hospital, Wuhan City, Hubei Province, China where the causative virus, SARS-CoV 2 originated. As the authors describe, this was one of the rapidly built COVID-19 hospitals established to cope with this serious epidemic.

The authors describe in detail the SARS-CoV 2 PCR test used to diagnose COVID-19. If they are only referred “confirmed COVID-19” positive patients, why were patients tested for SARS-CoV 2? Was this a confirmatory test following a PCR result at the referring hospital? Was it the initial diagnostic test? This is not clear. I could not see information on numbers of tests performed at Tongji Hospital or positivity rate in this cohort of 799 patients.

What happened if “confirmed COVID-19” patients referred by another hospital had a negative SARS-CoV 2 result at Tongji Hospital?

It would be interesting and helpful to have clarification of the testing strategy, rationale and test results in this early COVID-19 cohort in a designated COVID-19 hospital in Wuhan. This additional information would make this article even more valuable.

References:

1. Chen T et al. Clinical characteristics of 113 deceased patients with coronavirus 2019 : retrospective study. BMJ 2020;368 doi: https://doi.org/10.1136/bmj.m109 (accessed 2/4/20)

Competing interests: Any views expressed are my own and not those of my employer.

02 April 2020
Gee Yen Shin
Consultant Virologist
UCLH NHS Foundation Trust
UCLH NHS Foundation Trust, London, United Kingdom